UNIGE document Scientific Article
previous document  unige:90219  next document
add to browser collection
Title

A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin

Authors
Nilubol, Naris
Merkel, Roxanne
Yang, Lily
Patel, Dhaval
Reynolds, James C
Neychev, Vladimir
Kebebew, Electron
Published in Clinical Endocrinology. 2016, vol. n/a
Abstract Valproic acid (VA) is a histone deacetylase (HDAC) inhibitor that has antiproliferative effects on several types of cancer, including thyroid cancer. In addition, VA has been reported to upregulate the sodium-iodine symporter in thyroid cancer cells and increases radioiodine uptake in preclinical studies. The aim of this study was to assess the antiproliferative effects of VA and to evaluate if VA can increase the radioiodine uptake in patients with advanced, radioiodine-negative thyroid cancer.
Identifiers
PMID: 27392538
Full text
Article (Published version) (179 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research group Mésothéliome pleural malin (944)
Citation
(ISO format)
NILUBOL, Naris et al. A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin. In: Clinical Endocrinology, 2016, vol. n/a. https://archive-ouverte.unige.ch/unige:90219

43 hits

0 download

Update

Deposited on : 2016-12-09

Export document
Format :
Citation style :